GlassScriptPhysician profile
Ronald D Sheppard
NPI 1902873094
$643.79
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $292 · 2021: $17.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $112.99 | 2019-2020 | |
| Allergan, INC. | $83.48 | 2019-2020 | |
| Amarin Pharma, INC. | $64.15 | 2019-2020 | |
| Pfizer INC. | $60.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.74 | 2020 | |
| Novo Nordisk INC | $51.53 | 2019-2020 | |
| Abbvie INC. | $43.11 | 2019 | |
| Amgen INC. | $29.40 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.61 | 2019 | |
| Vifor Pharma, INC. | $22.08 | 2020 | |
| Merck Sharp & Dohme LLC | $17.19 | 2021 | |
| Glaxosmithkline, LLC. | $15.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.83 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11.41 | 2020 | |
| Circassia INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.